NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

European Journal of Cancer

Volumn 39, Issue 8, 2003, Pages 1176-1183

  Woon, S T ^a   Zwain, S ^a   Schooltink, M A ^a   Newth, A L ^a   Baguley, B C ^a   Ching, L M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anticancer agent; Antivascular; DMXAA; NF kappa B; TNF

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; CYTOKINE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; PROTEIN SUBUNIT; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MUTANT; CELL NUCLEUS; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; GENE TRANSLOCATION; IMMUNITY; LYMPHOMA; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; TARGET CELL; TUMOR GROWTH; TUMOR REGRESSION;

EID: 0037726779     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00196-5     Document Type: Article

References (32)

1. Rewcastle G.W., Atwell G.J., Zhuang L., Baguley B.C., Denny W.A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 34:1991;217-222.
2. Jameson M.B., Thompson P.I., Baguley B.C.et al. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc. Am. Soc. Clin. Oncol. 19:2000;182a.
3. Zwi L.J., Baguley B.C., Gavin J.B., Wilson W.R. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol. Res. 6:1994;79-85.
4. Lash C.J., Li A.E., Rutland M., Baguley B.C., Zwi L.J., Wilson W.R. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer. 78:1998;439-445.
5. Perera P.Y., Barber S.A., Ching L.M., Vogel S.N. Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages- dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. J. Immunol. 153:1994;4684-4693.
6. Cao Z., Baguley B.C., Ching L.-M. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 61:2001;1517-1521.
7. Joseph W.R., Cao Z., Mountjoy K.G., Marshall E.S., Baguley B.C., Ching L.-M. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid. a novel approach to cancer therapy Cancer Res. 59:1999;633-638.
8. Ching L.M., Goldsmith D., Joseph W.R., Korner H., Sedgwick J.D., Baguley B.C. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 59:1999;3304-3307.
9. Zhao L., Ching L.M., Kestell P., Baguley B.C. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br. J. Cancer. 87:2002;465-470.
10. Woon S.-T., Baguley B.C., Palmer B.D., Fraser J.D., Ching L.-M. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappa B in human tumor cell lines. Oncol. Res. 13:2002;95-101.
11. Wang C.Y., Mayo M.W., Baldwin A.S. TNF- and cancer therapy-induced apoptosis - potentiation by inhibition of NF-kappaB. Science. 274:1996;784-787.
12. Courtois G., Whiteside S.T., Sibley C.H., Israel A. Characterization of a mutant cell line that does not activate NF-kappa-B in response to multiple stimuli. Mol. Cell. Biol. 17:1997;1441-1449.
13. Rothwarf D.M., Zandi E., Natoli G., Karin M. IKK-gamma is an essential regulatory subunit of the I-kappa-B kinase complex. Nature. 395:1998;297-300.
14. Baguley B.C., Calveley S.B., Crowe K.K., Fray L.M., O'Rourke S.A., Smith G.P. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on Colon 38 tumors in mice. Eur. J. Cancer Clin. Oncol. 25:1989;263-269.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival. application to proliferation and cytotoxicity assays J. Immunol. Meth. 65:1983;55-63.
16. Ching L.M., Young H.A., Eberly K., Yu C.-R. Induction of STAT and NF kappa B activation by the antitumour agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line. Biochem. Pharmacol. 58:1999;1173-1181.
17. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities or protein utilizing the principle of protein-dye binding. Analyt. Biochem. 72:1976;248-254.
18. Sen R., Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell. 47:1986;921-928.
19. Rice N.R., Ernst M.K. In vivo control of NF-kappa B activation by I kappa B alpha. EMBO J. 12:1993;4685-4695.
20. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta. Nature. 396:1998;77-80.
21. Philpott M., Ching L.M., Baguley B.C. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator to other inducers of tumour necrosis factor. Eur. J. Cancer. 37:2001;1930-1937.
22. Karin M. The beginning of the end. I kappa B kinase (IKK) and NF-kappa B activation J. Biol. Chem. 274:1999;27339-27342.
23. Ching L.-M., Cao Z., Kieda C., Zwain S., Jameson M.B., Baguley B.C. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer. 86:2002;1937-1942.
24. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 18:1999;6910-6924.
25. Ching L.M., Joseph W.R., Baguley B.C. Effect of tumour growth on the macrophage response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Anticancer Res. 13:1993;2069-2075.
26. Creasey A.A., Reynolds M.J., Laird W. Cures and partial regresion of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res. 46:1986;5687-5690.
27. Baguley B.C. Small-molecule cytokine inducers causing tumor necrosis. Curr. Opin. Investig. Drugs. 2:2001;967-975.
28. Kestell P., Paxton J.W., Rewcastle G.W., Dunlop I., Baguley B.C. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethyl-xanthenone-4-acetic acid in mouse, rat and rabbit. Cancer Chemother. Pharmacol. 43:1999;323-330.
29. Zhao L., Kestell P., Ching L.-M., Baguley B.C. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer Chemother. Pharmacol. 49:2002;20-26.
30. Baguley B.C., Wilson W.R. Potential of DMXAA combination therapy for solid tumors. Expert Rev. Anticancer Ther. 2:2002;593-603.
31. Baguley B.C., Zhuang L., Marshall E. Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemother. Pharmacol. 36:1995;244-248.
32. Bentires-Alj M., Hellin A.C., Ameyar M., Chouaib S., Merville M.P., Bours V. Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res. 59:1999;811-815.